Search results for: Antoni Ribas

Items from 1 to 20 out of 105 results

article

Interleukin 32 expression in human melanoma

Helicia Paz, Jennifer Tsoi, Anusha Kalbasi, Catherine S. Grasso, more

Journal of Translational Medicine > 2019 > 17 > 1 > 1-13

Background Various proinflammatory cytokines can be detected within the melanoma tumor microenvironment. Interleukin 32 (IL32) is produced by T cells, NK cells and monocytes/macrophages, but also by a subset of melanoma cells. We sought to better understand the biology of IL32 in human melanoma. Methods We analyzed RNA sequencing data from 53 in-house established human melanoma cell lines and 479...

article

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

Vylyny Chat, Robert Ferguson, Danny Simpson, Esther Kazlow, more

Cancer Immunology, Immunotherapy > 2019 > 68 > 6 > 897-905

Immune-checkpoint inhibition (ICI) treatments improve outcomes for metastatic melanoma; however, > 60% of treated patients do not respond to ICI. Current biomarkers do not reliably explain ICI resistance. Given the link between ICI and autoimmunity, we investigated if genetic susceptibility to autoimmunity modulates ICI efficacy. In 436 patients with metastatic melanoma receiving single line ICI...

article

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Matteo S. Carlino, Georgina V. Long, Dirk Schadendorf, Caroline Robert, more

European Journal of Cancer > 2018 > 101 > C > 236-243

Predictive biomarkers of patients likely to benefit from anti–programmed death 1 inhibitor therapy have clinical relevance. We examined whether line of therapy or tumour programmed death ligand 1 (PD-L1) expression affects the efficacy and safety of pembrolizumab, compared with ipilimumab, in advanced melanoma.Of 834 patients enrolled in the randomised, open-label phase III KEYNOTE-006 study, 833...

article

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari VanderWalde, more

Cell > 2018 > 174 > 4 > 1031-1032

article

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Matthew J. Wongchenko, Antoni Ribas, Brigitte Dréno, Paolo A. Ascierto, more

Pigment Cell & Melanoma Research > 31 > 4 > 516 - 522

The prognostic significance of programmed death ligand‐1 (PD‐L1) on treatment outcomes in patients receiving BRAF with or without MEK inhibitors is not well understood. This retrospective exploratory analysis evaluated the association of tumour PD‐L1 expression with progression‐free survival (PFS) and overall survival (OS) among 210 patients in the coBRIM trial treated with cobimetinib plus vemurafenib...

article

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

Jennifer Tsoi, Lidia Robert, Kim Paraiso, Carlos Galvan, more

Cancer Cell > 2018 > 33 > 5 > 890-904.e5

Malignant transformation can result in melanoma cells that resemble different stages of their embryonic development. Our gene expression analysis of human melanoma cell lines and patient tumors revealed that melanoma follows a two-dimensional differentiation trajectory that can be subclassified into four progressive subtypes. This differentiation model is associated with subtype-specific sensitivity...

article

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Masoud F. Tavazoie, Ilana Pollack, Raissa Tanqueco, Benjamin N. Ostendorf, more

Cell > 2018 > 172 > 4 > 825-840.e18

Therapeutic harnessing of adaptive immunity via checkpoint inhibition has transformed the treatment of many cancers. Despite unprecedented long-term responses, most patients do not respond to these therapies. Immunotherapy non-responders often harbor high levels of circulating myeloid-derived suppressor cells (MDSCs)—an immunosuppressive innate cell population. Through genetic and pharmacological...

article

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

David Carbone, Michael Sharpnack, Kai He, Lisa H. Butterfield, more

Journal of Translational Medicine > 2018 > 16 > 1 > 1-15

article

Endocrinopathies with use of cancer immunotherapies

Natalie M. Villa, Abtin Farahmand, Lin Du, Michael W. Yeh, more

Clinical Endocrinology > 88 > 2 > 327 - 332

Background Immunomodulatory therapies, including CTLA‐4 and PD‐1 inhibitors, provide a directed attack against cancer cells by preventing T cell deactivation. However, these drugs also prevent the downregulation of auto‐reactive T cells, resulting in immune‐related adverse events (IRAEs). Reports show a varied incidence of endocrine IRAEs, ranging from 0% to 63%. Objective To describe the frequency...

article

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

Omid Hamid, Igor Puzanov, Reinhard Dummer, Jacob Schachter, more

European Journal of Cancer > 2017 > 86 > C > 37-45

To evaluate the protocol-specified final analysis of overall survival (OS) in the KEYNOTE-002 study (NCT01704287) of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory, advanced melanoma.In this randomised, phase II study, eligible patients had advanced melanoma with documented progression after two or more ipilimumab doses, previous BRAF or MEK inhibitor or both, if BRAF^V600...

article

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, more

The Lancet > 2017 > 390 > 10105 > 1853-1862

Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis. In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia,...

article

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari VanderWalde, more

Cell > 2017 > 170 > 6 > 1109-1119.e10

Here we report a phase 1b clinical trial testing the impact of oncolytic virotherapy with talimogene laherparepvec on cytotoxic T cell infiltration and therapeutic efficacy of the anti-PD-1 antibody pembrolizumab. Twenty-one patients with advanced melanoma were treated with talimogene laherparepvec followed by combination therapy with pembrolizumab. Therapy was generally well tolerated, with fatigue,...

article

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Dirk Schadendorf, Georgina V. Long, Daniil Stroiakovski, Boguslawa Karaszewska, more

European Journal of Cancer > 2017 > 82 > C > 45-55

Understanding predictors of long-term benefit with currently available melanoma therapies is the key for optimising individualised treatments. A prior pooled analysis of dabrafenib plus trametinib (D + T)–randomised trials (median follow-up, 20.0 months) identified baseline lactate dehydrogenase (LDH) and number of organ sites with metastasis as predictive factors for progression-free (PFS) and overall...

article

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, more

The Lancet Oncology > 2017 > 18 > 9 > 1202-1210

Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab. In this open-label, phase 1b trial, we recruited patients from 12 medical centres...

article

Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

Selma Ugurel, Joachim Röhmel, Paolo A. Ascierto, Keith T. Flaherty, more

European Journal of Cancer > 2017 > 83 > C > 247-257

The treatment of metastatic melanoma is still undergoing a process of major change. The two most important novel therapeutic strategies, selective kinase inhibitors and immune checkpoint blockers, both significantly prolong survival times of patients with advanced metastatic disease. Different agents, dose regimens and combinations have been tested against each other vigorously within these two groups...

article

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Luis Cruz-Merino, Lorenza Guardo, Jean-Jacques Grob, Alfredo Venosa, more

Journal of Translational Medicine > 2017 > 15 > 1 > 1-9

Background Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF^V600-mutated melanoma treated in the Phase III coBRIM study. Methods In the coBRIM study, 493 patients were treated in two randomly assigned treatment groups: cobimetinib and vemurafenib (n = 247)...

article

SnapShot: Immune Checkpoint Inhibitors

Gabriel Abril-Rodriguez, Antoni Ribas

Cancer Cell > 2017 > 31 > 6 > 848-848.e1

Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance). A better understanding of the molecular mechanisms underlying checkpoint blockade therapies will facilitate...

article

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Angel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, Justin Saco, more

Cell Reports > 2017 > 19 > 6 > 1189-1201

PD-L1 and PD-L2 are ligands for the PD-1 immune inhibiting checkpoint that can be induced in tumors by interferon exposure, leading to immune evasion. This process is important for immunotherapy based on PD-1 blockade. We examined the specific molecules involved in interferon-induced signaling that regulates PD-L1 and PD-L2 expression in melanoma cells. These studies revealed that the interferon-gamma-JAK1/JAK2-STAT1/STAT2/STAT3-IRF1...

article

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A. Wargo, Antoni Ribas

Cell > 2017 > 168 > 4 > 707-723

Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers of a wide range of histologies. Broadening the clinical applicability of these treatments requires an improved understanding of the mechanisms limiting cancer immunotherapy. The interactions between the immune system and cancer cells are continuous, dynamic, and evolving from the initial establishment of a cancer...

article

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Willy Hugo, Jesse M. Zaretsky, Lu Sun, Chunying Song, more

Cell > 2017 > 168 > 3 > 542

Publication date

Set your own date range

Content availability

Available (97)
None (8)

Publication type

article (104)
book (1)

Publication language

English (105)
German (1)

Keywords

MELANOMA (24)
IMMUNOTHERAPY (11)
CANCER (5)
VEMURAFENIB (5)
METASTATIC MELANOMA (4)
PEMBROLIZUMAB (4)
AUTOIMMUNITY (3)
DABRAFENIB (3)
DENDRITIC CELLS (3)
PD-L1 (3)
SURVIVAL (3)
THERAPY (3)
TRAMETINIB (3)
BRAF (2)
BRAF INHIBITOR (2)
CANCER DIAGNOSIS (2)
CHEMOTHERAPY (2)
CIRCULATING TUMOR CELLS (2)
CLINICAL TRIAL (2)
COBIMETINIB (2)
COMBINATION THERAPY (2)
EINZELZELLANALYSE (2)
IMMUNE CHECKPOINT BLOCKERS (2)
KINASE INHIBITORS (2)
KREBS (2)
KREBSDIAGNOSE (2)
MAPK (2)
MEK INHIBITION (2)
MELANOME (2)
NRAS (2)
PD-1 (2)
RODENT (2)
SINGLE‐CELL ANALYSIS (2)
T LYMPHOCYTES (2)
TARGETED THERAPY (2)
TREMELIMUMAB (2)
TUMOR IMMUNOTHERAPY (2)
TUMOR MICROENVIRONMENT (2)
ZIRKULIERENDE TUMORZELLEN (2)
ABI‐007 (ABRAXANE) (1)
ACQUIRED (1)
ACQUIRED RESISTANCE (1)
ACRAL MELANOMA (1)
ADOPTIVE CELL TRANSFER (1)
ADVANCED MELANOMA (1)
ALPHA FETOPROTEIN (1)
ANTI-CTLA-4 THERAPY (1)
ANTI-PD-1 (1)
ANTIBODY FUSION PROTEINS (1)
ANTIGENIC PEPTIDES (1)
ANTI‐PROGRAMMED CELL DEATH RECEPTOR 1 (ANTI‐PD‐1) (1)
APOE (1)
BCL-2 (1)
BIOMARKER (1)
BIOMARKERS (1)
BLOOD TRANSFUSIONS (1)
BRAF MUTANT (1)
BRAIN TUMOR (1)
CANCER IMMUNOTHERAPY (1)
CANCER VACCINE (1)
CELECOXIB (1)
CHRONIC HEPATITIS (1)
COX-2 (1)
CTLA-4 (1)
CTLA4 (1)
CYCLIN D3 (1)
CYTOKINE (1)
CYTOTIXIC (1)
DACARBAZINE (1)
DIFFERENTIATION (1)
DORMANCY (1)
EARLY DIAGNOSIS (1)
EORTC QLQ-C30 (1)
ERK INHIBITOR (1)
EYE (1)
FERROPTOSIS (1)
GAMMA‐SECRETASE INHIBITOR (1)
GERMLINE VARIANTS (1)
HEALTH-RELATED QUALITY OF LIFE (1)
HEPATITIS C VIRUS (1)
HEPATOCELLULAR CARCINOMA (1)
HER2/NEU (1)
HGF (1)
HLA-A2.1 (1)
HYPERTHYROIDISM (1)
HYPOPITUITARISM (1)
IL32 TRANSCRIPTIONAL REGULATION (1)
IMEXON (1)
IMMUNE CHECKPOINT BLOCKADE (1)
IMMUNE INFILTRATION (1)
IMMUNE THERAPY (1)
IMMUNE-CHECKPOINT INHIBITION (1)
IMMUNOHISTOCHEMISTRY (1)
IMMUNOLOGICAL MONITORING (1)
IMMUNOLOGICAL SYNAPSE (1)
INTERFERON GAMMA (1)
INTERFERON RECEPTOR SIGNALING PATHWAYS (1)
INTERLEUKIN 32 (IL32) (1)
IPILIMUMAB-REFRACTORY (1)
IPILIMUMAB-REFRACTORY MELANOMA (1)
more

Data set

Elsevier (58)
Springer (28)
Wiley (18)
ACS (1)

Journal

European Journal of Cancer (10)
Journal for ImmunoTherapy of Cancer (10)
The Lancet Oncology (8)
Cell (7)
Journal of Translational Medicine (7)
Pigment Cell & Melanoma Research (7)
Cancer Immunology, Immunotherapy (5)
Cancer (4)
Cancer Cell (4)
Clinical Immunology (3)
Molecular Cancer (3)
Molecular Therapy (3)
The Lancet (3)
Angewandte Chemie (2)
Angewandte Chemie International Edition (2)
Current Opinion in Immunology (2)
Molecular Immunology (2)
Seminars in Oncology (2)
The Journal of Urology (2)
American Journal of Ophthalmology (1)
BMC Cancer (1)
Cell Reports (1)
Clinical Endocrinology (1)
Clinics in Dermatology (1)
Controlled Clinical Trials (1)
European Urology (1)
Gastroenterology (1)
Histopathology (1)
Investigational New Drugs (1)
Journal of the American Chemical Society (1)
Leukemia Research (1)
Molecular Oncology (1)
Seminars in Immunology (1)
The Journal of Pathology (1)
Trends in Immunology (1)
Update on Cancer Therapeutics (1)
Urology (1)
more

INFONA - science communication portal

Search results for: Antoni Ribas

Interleukin 32 expression in human melanoma

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Endocrinopathies with use of cancer immunotherapies

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

SnapShot: Immune Checkpoint Inhibitors

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Filter options

Publication date

Content availability

Publication type

Publication language

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Antoni Ribas

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Publication language

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options